Levofloxacin for the treatment of community-acquired pneumonia.
New respiratory fluoroquinolones (FQs), such as levofloxacin, offer many improved qualities over older agents, such as ciprofloxacin. These include retaining excellent Gram-negative bacilli activity, with improved Gram-positive activity. New FQ-like levofloxacin possesses greater bioavailabilty and a longer serum half-life compared with ciprofloxacin, allowing for once-daily dosing, which may improve patient adherence. The high bioavailability of levofloxacin allows for rapid step-down from intravenous administration to oral therapy, minimizing unnecessary hospitalization, which may decrease costs and improve patient quality of life. Levofloxacin has been evaluated for the treatment of community-acquired pneumonia (CAP) in numerous randomized clinical trials. Most published studies have used the 500 mg dose, although more recent studies have investigated the 750 mg dose once daily. These trials demonstrate that levofloxacin is effective and safe for the treatment of CAP, displaying relatively mild adverse effects that are more or less comparable with ciprofloxacin. Levofloxacin has much to offer in terms of bacterial eradication, including for resistant respiratory pathogens. However, ciprofloxacin-resistant organisms are becoming more prevalent so prudence must be exercised when prescribing this agent.
Lynch
Joseph P
JP
University of California, Los Angeles, Division of Pulmonary, Critical Care Medicine & Hospitalists, The David Geffen School of Medicine, Los Angeles, CA, USA. jlynch@mednet.ucla.edu
File
Thomas M
TM
Zhanel
George G
GG
D017714:Community-Acquired Infections / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism
D064704:Levofloxacin; D015242:Ofloxacin